Pharmaceutical

INCB-57643 by Incyte for Myelofibrosis: Likelihood of Approval

INCB-57643 is under clinical development by Incyte and currently in Phase II for Myelofibrosis.

Feb 8, 2024 - 18:00
INCB-57643 is under clinical development by Incyte and currently in Phase II for Myelofibrosis.
Read the original article

Tags:

Previous Article

STAT+: Pharmalittle: We’re reading about a lawsuit against J&J, Express Scripts ...

Next Article

AFM-24I by Affimed for Metastatic Hepatocellular Carcinoma (HCC): Likelihood of ...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Twist Bioscience and Bayer partner for antibody discovery

Twist Bioscience and Bayer partner for antibody discovery

Oct 7, 2023

La ‘paradoja hispana’ intriga a una nueva generación de investigadores decididos a resolverla

La ‘paradoja hispana’ intriga a una nueva generación de...

Nov 1, 2023

STAT+: Vertex non-opioid therapy reduced pain in mid-stage trials, study shows

STAT+: Vertex non-opioid therapy reduced pain in mid-st...

Aug 3, 2023